Compare NZF & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NZF | TWST |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 3.0B |
| IPO Year | 2001 | 2018 |
| Metric | NZF | TWST |
|---|---|---|
| Price | $12.87 | $48.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $48.75 |
| AVG Volume (30 Days) | 645.5K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | N/A | $18.89 |
| Revenue Next Year | N/A | $15.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $10.98 | $23.30 |
| 52 Week High | $13.02 | $57.88 |
| Indicator | NZF | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 60.82 | 57.00 |
| Support Level | $12.73 | $46.96 |
| Resistance Level | $13.02 | $57.88 |
| Average True Range (ATR) | 0.11 | 3.23 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 75.41 | 42.26 |
Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.